Advertisement
UK markets closed

  • FTSE 100

    8,420.26
    -18.39 (-0.22%)
     

  • FTSE 250

    20,749.90
    -72.94 (-0.35%)
     

  • AIM

    794.02
    +1.52 (+0.19%)
     

  • GBP/EUR

    1.1683
    +0.0028 (+0.24%)
     

  • GBP/USD

    1.2706
    +0.0035 (+0.28%)
     

  • Bitcoin GBP

    52,582.13
    +1,336.90 (+2.61%)
     

  • CMC Crypto 200

    1,360.67
    -13.17 (-0.96%)
     

  • S&P 500

    5,298.42
    +1.32 (+0.02%)
     

  • DOW

    39,948.47
    +79.09 (+0.20%)
     

  • CRUDE OIL

    80.08
    +0.85 (+1.07%)
     

  • GOLD FUTURES

    2,422.10
    +36.60 (+1.53%)
     

  • NIKKEI 225

    38,787.38
    -132.88 (-0.34%)
     

  • HANG SENG

    19,553.61
    +177.08 (+0.91%)
     

  • DAX

    18,704.42
    -34.39 (-0.18%)
     

  • CAC 40

    8,167.50
    -20.99 (-0.26%)
     
Property:

9 houses with great-looking gardens

Check out these homes if inspiring outside space tops your property wish list

Lantheus to Present at the Leerink Partners Global Biopharma Conference 2024

Lantheus Holdings, Inc.
·1-min read
Lantheus Holdings, Inc.
Lantheus Holdings, Inc.

BEDFORD, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Paul Blanchfield, President, will present at the Leerink Partners Global Biopharma Conference 2024 at 9:20 a.m. ET on Tuesday, March 12.

To access a live webcast of the presentation, please visit the Investors section of the Company’s website at www.lantheus.com. A replay of the webcast will be available on the Company’s website for at least 30 days following the live presentation.

About Lantheus
Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada and Sweden, Lantheus has been providing radiopharmaceutical solutions for more than 65 years. For more information, visit www.lantheus.com.

Contacts:
Mark Kinarney
Vice President, Investor Relations
978-671-8842
ir@lantheus.com

Melissa Downs
Senior Director, External Communications
646-975-2533
media@lantheus.com